MX2017015236A - Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation. - Google Patents

Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Info

Publication number
MX2017015236A
MX2017015236A MX2017015236A MX2017015236A MX2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A
Authority
MX
Mexico
Prior art keywords
acetylcysteine
glycine
supplementation
benefits
glutathione levels
Prior art date
Application number
MX2017015236A
Other languages
English (en)
Inventor
Kirnon Stephen
Freedland Eric
V Sekhar Rajagopal
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2017015236A publication Critical patent/MX2017015236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

La presente invención se refiere a composiciones y métodos que se relacionan con el uso de glicina y N-acetilcisteína en una variedad de afecciones médicas relacionadas con niveles reducidos de glicina, N-acetilcisteína, y/o glutatión.
MX2017015236A 2015-05-28 2016-05-25 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation. MX2017015236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167433P 2015-05-28 2015-05-28
PCT/US2016/034078 WO2016191468A1 (en) 2015-05-28 2016-05-25 Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels

Publications (1)

Publication Number Publication Date
MX2017015236A true MX2017015236A (es) 2018-11-09

Family

ID=57393662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015236A MX2017015236A (es) 2015-05-28 2016-05-25 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Country Status (10)

Country Link
US (4) US10952982B2 (es)
EP (1) EP3302459A4 (es)
JP (3) JP7074663B6 (es)
CN (2) CN115957294A (es)
AU (1) AU2016268340B2 (es)
BR (1) BR112017025499A2 (es)
CA (1) CA2987597A1 (es)
MX (2) MX2017015236A (es)
TW (1) TWI769981B (es)
WO (1) WO2016191468A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191468A1 (en) * 2015-05-28 2016-12-01 Baylor College Of Medicine Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels
WO2018075810A1 (en) * 2016-10-18 2018-04-26 Somahultion, Llc Dermatological compositions for providing nutrients to skin and methods thereof
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
BR112020006471A2 (pt) * 2017-11-21 2020-10-06 Société des Produits Nestlé S.A. composições e métodos que usam oleuropeína ou curcumina para massa muscular e/ou qualidade muscular
AU2019218232A1 (en) * 2018-02-09 2020-09-24 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
US20210228484A1 (en) * 2018-04-19 2021-07-29 Daniel BIDNER Veterinary thick gel composition of high palatability containing antioxidants to decrease sarcopenia, osteopenia and dna damage from oxidative stress in dogs, and procedure for its obtention
IT201800006566A1 (it) * 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
EP3810120A2 (en) * 2018-06-21 2021-04-28 Société des Produits Nestlé S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
CA3110296A1 (en) * 2018-09-27 2020-04-02 Societe Des Produits Nestle S.A. Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor
EP3856167A1 (en) 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Use of histidine, glycine and other aminoacids for preventing insulin resistance and/or diabetes
JP2022504702A (ja) 2018-11-02 2022-01-13 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
BR112021026551A2 (pt) * 2019-06-28 2022-02-15 Univ Kyushu Nat Univ Corp Ativador de função mitocondrial
CN110152004B (zh) * 2019-07-08 2021-09-03 天津医科大学 甘氨酸在制备药物递送增强剂及细胞移植试剂方面的用途
US11717554B2 (en) * 2019-09-19 2023-08-08 Max R&D Llc Method for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s)
US20230000806A1 (en) * 2019-11-18 2023-01-05 Societe Des Produits Nestle S.A. Compositions and methods for glutathione enhancement for use in brain health
WO2021127541A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2021198399A1 (en) * 2020-04-01 2021-10-07 Société des Produits Nestlé S.A. Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions
CA3177222A1 (en) 2020-04-29 2021-11-04 Societe Des Produits Nestle S.A. A nutritional product containing a buffer composition and an amino acid and methods of using such a nutritional product
US20210369661A1 (en) * 2020-05-27 2021-12-02 Immunoflex Therapeutics Inc. Methods and compositions for treating and recovering from viral infections
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792110A (en) * 1996-06-26 1998-08-11 Cunningham; Miles G. Systems and methods for delivering therapeutic agents to selected sites in a subject
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999043697A1 (en) * 1998-02-25 1999-09-02 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US7351427B2 (en) * 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2002087593A1 (en) * 2001-04-25 2002-11-07 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
US7175587B2 (en) * 2002-12-31 2007-02-13 Em-Probe, Inc. Method and apparatus for pulsed electromagnetic therapy
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
CA2679784A1 (en) * 2009-03-05 2010-09-05 Newcastle Innovation Limited Diagnostic, prognostic and treatment methods
US8796315B2 (en) * 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
US8916606B2 (en) * 2009-10-27 2014-12-23 William Marsh Rice University Therapeutic compositions and methods for targeted delivery of active agents
DK3777876T3 (da) * 2011-10-28 2023-10-30 Neostrata Company Inc N-acyldipeptid-derivater og anvendelser deraf
WO2013072714A1 (en) * 2011-11-15 2013-05-23 Centre National De La Recherche Scientifique (Cnrs) Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
CA2864040A1 (en) * 2012-02-07 2013-08-15 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
US8747894B2 (en) * 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
US20140006042A1 (en) * 2012-05-08 2014-01-02 Richard Keefe Methods for conducting studies
CN110051672A (zh) * 2012-07-09 2019-07-26 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
CA2958753C (en) * 2014-08-29 2021-09-07 Albert B. Crum A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US20160302451A1 (en) * 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
WO2016191468A1 (en) * 2015-05-28 2016-12-01 Baylor College Of Medicine Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels

Also Published As

Publication number Publication date
US20180161297A1 (en) 2018-06-14
US11730711B2 (en) 2023-08-22
JP7074663B2 (ja) 2022-05-24
WO2016191468A1 (en) 2016-12-01
US20210244696A1 (en) 2021-08-12
TWI769981B (zh) 2022-07-11
JP7074663B6 (ja) 2022-08-01
US10952982B2 (en) 2021-03-23
CA2987597A1 (en) 2016-12-01
MX2021014012A (es) 2022-01-06
TW201707696A (zh) 2017-03-01
JP2023022033A (ja) 2023-02-14
AU2016268340A1 (en) 2017-11-30
JP2018516280A (ja) 2018-06-21
CN115957294A (zh) 2023-04-14
AU2016268340B2 (en) 2021-07-08
EP3302459A4 (en) 2019-02-20
US20240041812A1 (en) 2024-02-08
CN107847475A (zh) 2018-03-27
EP3302459A1 (en) 2018-04-11
BR112017025499A2 (pt) 2018-08-07
US20230137543A1 (en) 2023-05-04
JP2021073181A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
MX2021014012A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2017000363A (es) Inhibicion de la via de notch.
MX2019011496A (es) Composiciones de niraparib.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
HK1252648A1 (zh) 氨基酸增補
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019007152A (es) Peptido novedoso.
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PH12017502028A1 (en) Vortioxetine pyroglutamate
PH12017501864A1 (en) Compositions and methods for treating autism
MX2016003207A (es) Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion.
TN2016000208A1 (en) Novel compound for treatment of severe hypoglycemia.
PH12017501944A1 (en) Method of making a mercury based compound, mercury based compound, methods of using the mercury based compound and uses of the mercury based compound
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
PH12018500967A1 (en) Soy sauce-like seasoning
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis